Brief: Knight Therapeutics Announces Health Canada Approval For Wynzora®
18/12/2025 12:48
Dec 18 (Reuters) - Knight Therapeutics Inc GUD.TO: KNIGHT THERAPEUTICS ANNOUNCES HEALTH CANADA APPROVAL FOR WYNZORA® TO TREAT PSORIASIS VULGARIS Source text: ID:nGNX5LlThG Further company coverage: GUD.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil